FindTrial
Sign In

A Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination Therapy

A Multicenter, Randomized, Double-blind, Active-controlled, Phase III Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination Therapy in Patients With Type 2 Diabetes Mellitus

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07816198
Enrollment
354
Registered
2026-09-11
Start date
2026-09-30
Completion date
2028-06-30
Last updated
2026-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus (T2DM)

Brief summary

The purpose of this study is to evaluate the efficacy and safety of AD-233A, AD-233B, AD-233C and/or AD-233D combination therapy

Detailed description

Condition or disease: Type 2 Diabetes Mellitus

Interventions

DRUGAD-233A

PO, Once daily(QD), 24 weeks

DRUGAD-233B

PO, Once daily(QD), 24 weeks

DRUGAD-233C

PO, Once daily(QD), 24 weeks

DRUGAD-233D

PO, Once daily(QD), 24 weeks

DRUGAD-233A Placebo

PO, Once daily(QD), 24 weeks

DRUGAD-233B Placebo

PO, Once daily(QD), 24 weeks

Sponsors

Addpharma Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Signed informed consent * Other inclusions applied

Exclusion criteria

* Subjects with severe diabetic complications * Other exclusions applied

Design outcomes

Primary

MeasureTime frame
Change in HbA1c(Hemoglobin a1c) from baseline at Week 24 after administration of IP(Investigator's Product)Baseline, Week 24

Contacts

CONTACTHanna Yang
hnyang@addpharma.co.kr82+01084267236
CONTACTSeong rae Kim, Principal Investigator

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 17, 2026